Ji-Young Sul

Ji-Young Sul

Auto-generated profile, based on publicly available information

Ji-Young Sul

Department of Surgery, Chungnam National University Hospital & Chungnam National University School of Medicine, Daejeon 35015, Republic of Korea

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2012 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
JLjinsun lee
jinsun lee
JSJi Young Sul
Ji Young Sul
JPJun Beom Park
Jun Beom Park
MLMyung Sun Lee
Myung Sun Lee
ECEun Young Cha
Eun Young Cha
ECEil Sung Chang
Eil Sung Chang

22 November 2010 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
MLMyung Sun Lee
Myung Sun Lee
CLChang Min Lee
Chang Min Lee
ECEun Young Cha
Eun Young Cha
PTPhuong Thien Thuong
Phuong Thien Thuong
KBKiHwan Bae
KiHwan Bae
JSJi Young Sul
Ji Young Sul

3 July 2018 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
JPJun Beom Park
Jun Beom Park
JLjinsun lee
jinsun lee
MLMyung Sun Lee
Myung Sun Lee
ECEun Young Cha
Eun Young Cha
SKSoyeon Kim
Soyeon Kim
JSJi Young Sul
Ji Young Sul
5‑Fluorouracil (5‑FU) is one of the most commonly used chemotherapeutic agents for gastric cancer. Resistance to 5‑FU‑based chemotherapy remains the major obstacle in the treatment of gastric cancer. A growing body of evidence has suggested that adenosine monophosphate‑activated protein kinase (AMPK) is pivotal for chemoresistance. However, the mechanism by which AMPK regulates the chemosensitivity of gastric cancer remains unclear. In the present study, how corosolic acid enhanced the chemosensitivity of gastric cancer cells to 5‑FU via AMPK activation was investigated. A 5‑FU‑resistant gastric cancer cell line (SNU‑620/5‑FUR) was established, which had a marked increase in thymidine synthase (TS) expression but reduced AMPK phosphorylation when compared with the parental cell line, SNU‑620. AMPK regulation by 5‑aminoimidazole‑4‑carboxamide ribonucleotide or compound c was revealed to be markedly associated with TS expression and 5‑FU‑resistant cell viability. In addition, corosolic acid activated AMPK, and decreased TS expression and the phosphorylation of mammalian target of rapamycin/4E‑binding protein 1 in a dose‑dependent manner. Corosolic acid treatment significantly reduced cell viability while compound c reversed corosolic acid‑induced cell growth inhibition. The 5‑FU‑resistance sensitization effect of corosolic acid was determined by the synergistic reduction of TS expression and inhibition of cell viability in the presence of 5‑FU. The corosolic acid‑induced AMPK activation was markedly increased by additional 5‑FU treatment, while compound c reversed AMPK phosphorylation. In addition, compound c treatment reversed corosolic acid‑induced apoptotic markers such as capase‑3 and PARP cleavage, and cytochrome c translocation to cytosol, in the presence of 5‑FU. Corosolic acid treatment in the presence of 5‑FU induced an increase in the apoptotic cell population based on flow cytometry analysis. This increase was abolished by compound c. In conclusion, these results implied that corosolic acid may have therapeutic potential to sensitize the resistance of gastric cancer to 5‑FU by activating AMPK.

22 June 2015 in Molecular Medicine Reports
Verified
Journal Article
Closed access
PDF file
HLHyun Su Lee
Hyun Su Lee
JPJun Beom Park
Jun Beom Park
MLMyung Sun Lee
Myung Sun Lee
ECEun Young Cha
Eun Young Cha
JKJi Yeon Kim
Ji Yeon Kim
JSJi Young Sul
Ji Young Sul
5‑Fluorouracil (5‑FU), one of the oldest anticancer therapeutic agents, is increasingly being administered in cancer chemotherapy. In the present study, the anticancer effects of 5‑FU combined with corosolic acid (CRA) were determined in SNU‑620 human gastric carcinoma cells and the underlying mechanisms were examined. A combination treatment of 5‑FU and CRA inhibited the viability of cells additively. Furthermore, apoptotic activity following combination treatment was found to be stronger than that of the single treatments, as observed using an Annexin V/propidium iodide assay. The protein level of Bcl‑2 was decreased significantly by the combination treatment, whereas the protein level of Bim was increased. The release of mitochondrial cytochrome c was increased as a result of the combination treatment, however, the combination treatment additively increased caspase‑3 and poly‑(ADP‑ribose) polymerase cleavages. Additionally, the mammalian target of rapamycin (mTOR) signaling pathway, which is highly activated in gastric cancer, was regulated by 5‑FU and CRA, and additive mTOR/eukaryotic translation initiation factor 4E‑binding protein 1 (4‑EBP1) inhibition was observed with the combination treatment. Additional rapamycin treatment along with the combination treatment of 5‑FU and CRA showed a more marked inhibition of mTOR/4‑EBP1 in the cells, as well as increased apoptosis and antiproliferation. Thus, these data indicate that CRA enhances the anticancer activities of 5‑FU via mTOR inhibition in SNU‑620 human gastric carcinoma cells.

15 June 2020 in Journal of Minimally Invasive Surgery
Verified
Journal Article
Open access
HKHyun Jeong Ki
Hyun Jeong Ki
JPJun Beom Park
Jun Beom Park
JSJi-Young Sul
Ji-Young Sul
M.M.D.
M.D.
PHPh.D.
Ph.D.
The port site hernia (PSH) is a specific type of incisional hernia related to the trocar sites of laparoscopic surgery. Diastasis recti of the abdominis muscle (DR) is the separation of the rectus muscle by a certain distance. The present study aims to present our experience with umbilical PSH and concomitant DR and to raise awareness of DR as one of the risk factors of umbilical PSH. Eighteen patients with umbilical PSH after laparoscopic abdominal surgery, was retrospectively reviewed. Preoperative CT was analyzed to measure the Inter-recti distance (IRD) for all patients. Other factors, such as trocar size, wound infection, obesity (BMI), port extension, suture materials, and pre-existing co-morbidities, were recorded and analyzed. Extension of the port incision was associated with umbilical PSH. Ten out of eighteen umbilical PSH patients (56%) had DR before they had first laparoscopic surgery. Nine (50%) patients showed sarcopenia. Moreover, four out of five recurrences had DR. More than two recurrences were all associated with DR. Port extension and sarcopenia were risk factors of umbilical PSH. Also, DR might be a possible risk factor of umbilical PSH occurrence and recurrence. Surgeons should be aware of the presence of DR before the planning of the laparoscopic surgery by diagnostic imaging. If DR is associated with umbilical PSH, we need to consider the correction of both pathologies at the same time.

1 January 2025 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
HKHyunjeong Ki
Hyunjeong Ki
SKSeyoung Koo
Seyoung Koo
GKGil Ho Kang
Gil Ho Kang
JSJiyoung Sul
Jiyoung Sul
JPJun Beom Park
Jun Beom Park
Ki H, et al. Ann Surg Treat Res. 2025 Apr;108(4):211-218. https://doi.org/10.4174/astr.2025.108.4.211